One hundred out of 854 investigated patients underwent genetic counseling and subsequent germline testing for MMR and EPCAM genes for suspected LS, and divided into three subgroups on the basis of the following criteria: tumor MMR deficiency (detected through IHC), Amsterdam criteria II, and revised Bethesda guidelines (Figure 1). This evidence concerns the gene EPCAM and Leigh syndrome.